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Abstract
Fanconi anemia (FA) is an autosomal-recessive disorder associated with hematopoietic failure and it is a candidate for
hematopoietic stem cell (HSC)-directed gene therapy. However, the characteristically reduced HSC numbers found in FA
patients, their ineffective mobilization from the marrow, and re-oxygenation damage during ex vivo manipulation have
precluded clinical success using conventional in vitro approaches. We previously demonstrated that lentiviral
vector (LV) particles reversibly attach to the cell surface where they gain protection from serum complement
neutralization. We reasoned that cellular delivery of LV to the bone marrow niche could avoid detrimental losses during
FA HSC mobilization and in vitro modification. Here, we demonstrate that a VSV-G pseudotyped lentivector, carrying the
FANCC transgene, can be transmitted from carrier to bystander cells. In cell culture and transplantation models of FA, we
further demonstrate that LV carrier cells migrate along SDF-1α gradients and transfer vector particles that stably integrate
and phenotypically correct the characteristic DNA alkylator sensitivity in murine and human FA-deficient target bystander
cells. Altogether, we demonstrate that cellular homing mechanisms can be harnessed for the functional phenotype
correction in murine FA hematopoietic cells.
Keywords: Fanconi Anemia, Gene Therapy, In situ gene delivery, Lentiviral vector, Hematopoietic stem cells, FA gene
therapy
Introduction
Fanconi anemia (FA) is a multisystem disorder resulting
from mutations in one of at least 22 genes that encode
the FANC family of DNA repair proteins [1, 2]. For most
patients, the associated bone marrow failure presents
the most pressing clinical issue. The hematopoietic stem
cell (HSC) attrition that underlies the typical cytopenias
appears to reflect a combination of accrued DNA dam-
age and an exaggerated susceptibility to innate immunity
or aldehyde detoxification [3, 4]. Curative allogeneic
stem cell transplantation, however, is available only to
patients with suitably matched related or unrelated
donors, and places them at risk of procedure-related
complications [5, 6]. As an alternative, several groups
are working to develop gene therapy methods to stably
correct the patient’s own HSCs, using retro- or lentiviral
vectors (LVs) [7, 8]. HSC-directed gene therapy has been
successfully used to treat several hematologic and
immunodeficiency disorders [9], but FA patients present
unique challenges. Typically, the bone marrow (BM)
cellularity of the patient is reduced, HSC numbers fol-
lowing G-CSF mobilization are low, and repopulation
properties are further lost during ex vivo transduction
culture [10–12]. Direct injection of viral vector particles
into the BM has been proposed to bypass ex vivo
manipulation of FA HSCs, but this strategy leads to
rapid dilutional losses, complement neutralization, and
vector sensitization [13, 14].
Several classes of enveloped viruses, including human
T-cell leukemia virus (HTLV-1), form viral ‘biofilms’ that
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non-specifically attach virion particles to cells [14]. In-
deed, direct biofilm-assisted cell-cell transfer increases
viral transmission and systemic distribution to distant
tissue sites [15, 16]. Cellular capture of human immuno-
deficiency virus (HIV) particles was also observed as a
mode of HIV transmission across genital and gastro-
intestinal mucosal surfaces [17]. We previously reported
that cell surface-bound HIV-1-derived LV particles gain
protection from serum neutralization and transfer be-
tween cells with relatively greater efficiency compared
with several cell-free virions [18, 19]. Here, we exploited
those observations in a strategy that combines in vitro
exposure of LV to “carrier” cells that traffic to the bone
marrow, thereby minimizing in vitro manipulation of FA
HSCs while achieving stable transduction through cellular
in situ delivery. To simulate the key steps in this process,
we systematically analyzed the role of chemotaxis to pro-
mote carrier cell migration to the hematopoietic niche.
Given its critical role in BM homing, C-X-C chemokine
receptor type 4 (CXCR4)-expressing leukemic cells L1210
and murine progenitors were used as carrier cells to
demonstrate chemotactic migration in vitro and in vivo,
respectively. Radiation of carrier cells prior to vector bind-
ing was used to avoid the persistence of carrier cells after
vector delivery to recipient cells. Results showed that
carrier cells can migrate along a chemotactic gradient of
stromal derived factor-1α (SDF-1α) and traffic FANCC
expressing LV to Fancc–/– murine hematopoietic stem and
progenitor cell (HSPC) target cells, with subsequent trans-
duction (TD) and expansion under selection pressure.
Results
In vitro cell-cell transfer of lentiviral vector
A lentiviral vector (LVCG) expressing GFP was used to
measure the cell-cell transfer rate of vector particles in
vitro. Carrier cells were generated by transducing human
embryonic kidney cell line (HEK293T) with a DsRed
expressing lentiviral vector (LV-DsRed) and enriched to
purity by flow cytometric sorting. Primary transduction
(1° TD) and secondary transduction (2° TD) to the by-
stander cells are detected based on the reporter protein
expression in the transduced cells (Fig. 1a). In this experi-
mental set-up, four fluorescence protein expression pat-
terns could be observed: non-transduced carrier 293 T-
DsRed cells, non-transduced wild-type 293 T cells, pri-
mary transduced (1° TD) 293 T (DsRed +GFP) cells, and
secondary transduced (2° TD) 293 T-GFP cells (Fig. 1b).
Radiation was used to selectively eliminate the carrier cells
after 2° TD. Results show that the irradiation (Ra) of car-
rier cells had no significant impact on vector transfer to 2°
recipient cells (Fig. 1c). Cells were maintained in culture
for up to 4 weeks to analyze both 1° and 2° transduced
cells. The projected depletion of irradiated carrier cells
over time and the stability of transgene expression from
integrated lentiviral vector was further confirmed by ana-
lyzing long-term culture (Fig. 1d).
To assess the stability of vector attachment to carrier
cells, cells incubated with vector were washed repeat-
edly, and followed each time by co-culture with the
recipient cells. The number of washes did not appear to
significantly affect the rate of secondary transduction,
suggesting that LV biofilms are not easily disrupted dur-
ing manipulation prior to contact with recipient cells
(Fig. 1e). To simulate 2° TD events after migration, we
used a murine leukemia cell line, L1210, which constitu-
tively overexpresses the chemokine receptor CXCR4.
Cells with CXCR4 receptor expression exhibit chemo-
taxis towards the SDF-1α. 293 T cells in SDF-1α supple-
mented medium were plated in the bottom chamber of
the transwell plate to facilitate 2° transduction after mi-
gration. Results indicate successful migration of L1210
cells along an SDF-1α gradient to the recipient 293 T
cells (Fig. 1f ). Given the direct competition between car-
rier and recipient cells for uptake and transduction by
vector particles, we observed anticipated losses to 1° TD
on carrier cells that occur during the course of cell-to-
cell transfer of vector particles for 2° TD recipient cells
(Fig. 1g). Overall, the experimental model of 2° TD after
migration of irradiated carrier cells supports its potential
for in situ gene delivery of therapeutic transgenes.
Functional correction in Fancc defective cells in vitro
Bystander cell transduction by LV particles using carrier
cell delivery has the potential for therapeutic phenotypic
correction of FA target cells located in an internal tissue
compartment. Here, we modeled cellular delivery by
using vector-bound HSPCs as carrier cells migrating by
chemotaxis towards PD331, a human FANCC–/– fibro-
blast recipient cell line maintained in SDF-1α containing
medium (Fig. 2a). Primary progenitor cells were used
from Tomato protein-expressing transgenic animals [20]
as carrier cells along with an HIV-based lentiviral vector
LV-GFP-FANCC that expresses a GFP reporter and
human FANCC for the phenotypic rescue. Co-culture of
HSPC-Tomato cells carrying vector with PD331 cells
resulted in the 2° TD of PD331 cells, indicated by GFP-
FANCC-positive PD331 cells (Fig. 2b).
Case reports suggest that selective clonal expansion
of spontaneously corrected HSPCs in FA patients can
correct peripheral blood cytopenias [21, 22]. To mimic
such a selection, we cultured phenotypically corrected
FA cells in the presence of the DNA alkylating agent
mitomycin-C (MMC). Results demonstrate significant
2° TD in the presence of SDF-1α while MMC enriches
the transduced cells post-delivery (Fig. 2c). The FA
pathway is known to be activated in response to MMC-
induced DNA damage [21]. A gain in mean florescent
intensity (MFI) of GFP from the GFP-FANCC fusion
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protein cassette was observed (Fig. 2d) in 2° transduced
PD331 cells, suggesting phenotypic rescue by the GFP-
FANCC transgene expression. Genomic DNA was
extracted from the 2° transduced PD331 cells to analyze
the vector DNA status in these cells by PCR using pri-
mer combination of poly purine tract (PPT Forward
primer) from vector backbone and transgene (GFP-Re-
verse primer) expression unit. Proviral integration and
the status of GFP-FANCC transgene cassette was con-
firmed in these 2° TD PD331 cells (Fig. 2e). When the
2° transduced PD331 cells are maintained in the pres-
ence of MMC, the ongoing selection pressure enriched
the PD331-GFP-FANCC cells rapidly (Fig. 2f ). The
successful selection of corrected FA phenotype cells in
vitro suggests the feasibility of translating this approach
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Fig. 1 Factors affecting 2° TD. a Schematic representation of experimental design. DsRed expressing 293 T cells were used as carrier cells incubated with
LV-GFP for 3 h followed by washes. The vector-coated carrier cells are then incubated overnight with 293 T cells in 1:1 ratio. Primary transduced (1° TD) cells
will be double-positive for GFP and DsRed and secondary transduced (2° TD) cells will be GFP-positive. b Microscopic imaging of 1° TD and 2° TD HEK293T
cells at 48 h post-transduction. c FACS analysis for fluorescent protein expression in HEK293T cell cultures to observe the fate of transduced
cells (n = 3). d Long-term analysis of 2° TD and the fate of irradiated carrier cell (shown as Ra) measured by FACS. e Rate of 2° TD is measured
after several washes of 1° TD cells with phosphate-buffered saline (PBS). f 2° TD in 293 T cells after transwell migration of murine L1210 cells towards
the SDF-1α gradient. L1210-DsRed carrier cells were irradiated and incubated with LV-GFP for 3 h followed by washes. The vector-coated carrier cells
are then incubated overnight with 293 T cells in 1:1 ratio. Cells were analyzed for up to 4 weeks. g FACS analysis of primary transduction rate in carrier
cells (n = 3; ***p > 0.0001). GFP green fluorescent protein, n/s not significant, SDF stromal-derived factor
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In vivo gene correction of Fancc-deficient hematopoietic
cells via cellular delivery of LV
The application of 2° TD for the delivery of a therapeutic
vector was analyzed in vivo by testing GFP-FANCC ex-
pressing LV in conjunction with carrier cells followed by
in vivo selection to expand the genetically corrected
HSPCs. Conceptually, the chemotactic migration to-
wards BM and the ability to shield the vector particles
from neutralizing antibodies suggests that hematopoietic
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Fig. 2 In vitro genetic correction and expansion of 2° TD FANCC–/– cells. a Diagram depicting the experimental steps of 2° TD in vitro. Tomato-positive
HSPC cells were used as carrier cells harboring the LV-GFP-FANCC vector to migrate across the transwell membrane to the bottom chamber for 2° TD
on the PD331 cells. b Microscopic imaging of 2° TD by using Tomato HSPC as a carrier and FANCC–/– PD331 as recipient cells. c Measurement of 2° TD
with experimental variables including radiation, DNA damage by MMC, and chemotaxis by SDF-1α. The combination of SDF-1α, radiation, and MMC
were also used as different parameters that affect 2° TD directly or indirectly (n = 6; ***p > 0.0001). d Mean florescent intensity (MFI) as a measure of
transgene expression. e PCR analysis of LV-GFP-FANCC status. f Expansion of FANCC-corrected 2° TD PD331 cells under MMC selection pressure (n = 3).
Con control, GFP green fluorescent protein, HSC hematopoietic stem cell, MMC mitomycin-C, n/s not significant, Ra irradiation,
SDF stromal-derived factor
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delivery of LV particles [19]. We used hematopoietic
progenitors as carriers derived from Tomato-positive
transgenic B57BL/6 J mice (Tomato HSPCs) for the de-
livery of LV-GFP-FANCC vector to the recipient cells
(CD45.1 HSPCs) [19]. The 2° TD events were measured
by GFP expression (FACS) and colony-forming assay to
confirm the intercellular transfer of LV between the
HSPCs. Consistent with earlier results, MMC exposure
of the 2° target improved post-transduction transgene
expression suggesting the protein response to induced
DNA damage (Fig. 3a) [23]. Vector transfer between car-
rier and recipient HSPCs was further analyzed by
colony-forming assay which allowed us to distinguish
colony-forming units from both 1° (Tomato + GFP)
versus 2° TD (GFP) events (Fig. 3b).
Finally, we determined in situ transduction rates
in vivo in Fancc KO (Fancc–/–) recipients (CD45.2)
following low-dose ionizing radiation (200 cGy)
conditioning to induce SDF-1α release and carrier cell
homing to the BM. We used lineage depleted (Lin–)
CD45.1 progenitors as carrier cells, irradiated at
1000 cGy to avoid post-delivery persistence, and ex-
posed these irradiated carrier cells to LV-GFP-FANCC
vector at MOI 20 for 6 h (Fig. 3c). To determine bone
marrow homing of vector-bound, irradiated HSPCs, we
measured CD45.1 chimerism (carrier) versus the
endogenous recipient cells (CD45.2 Fancc–/–) in the
peripheral blood (Fig. 3d). Predictably, recipient cells
represented a dominant fraction in transplanted ani-
mals and indicate the intended loss of irradiated carrier
cells as well as vector delivery to endogenous targets in
the bone marrow. To further boost the percentage of
phenotypically corrected Fancc–/– HSPCs, we used ser-
ial low doses of post-transplant ionizing radiation [24].
Remarkably, the 2° TD Fancc–/– KO animals showed a
consistently expanding population of GFP-FANCC
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Fig. 3 In situ gene delivery in FANCC–/– murine model. a Measurement of 2° TD by FACS between mT/mG HSPC as carrier cells and CD45.1
HSPCs as recipient cells (n = 3, **p < 0.001) b 1° and 2° transduced colony forming units (CFUs) expressing the corresponding florescent proteins.
c Schematic diagram of in situ gene delivery model for FANCC correction and expansion of corrected cells. d Chimerism of the recipient FANCC–/–
CD45.2 cells up to 3 months post-transplant (n = 4) e GFP-FANCC expression in the recipient (CD45.2) cells up to 3 months post-transplant indicating
2° TD events. Irradiation to induce selection pressure by DNA repair was given at weeks 6 and 11. Con control, GFP green fluorescent protein, HSPC
hematopoietic stem and progenitor cell, KO knockout, MMC mitomycin-C, PBC peripheral blood cells, Ra irradiation
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expressing cells (Fig. 2e), illustrating the in vivo selec-
tion and expansion of FA HSPCs via 2° TD.
Discussion
The same ex vivo manipulation of HSPCs successfully
utilized in several hematopoietic gene therapy trials
appears to impair the proliferation and repopulation
potential of FA HSPCs [25, 26]. An alternative direct
inoculation of vector into the bone marrow for trans-
duction of host cells, on the other hand, risks comple-
ment neutralization and the possibility of eliciting an
immune response [27]. By contrast, carrier cell surface
bound vector particles appear to escape neutralization
by serum complement [18], and the in situ gene deliv-
ery into the bone marrow stem cell compartment using
carrier cells has not been previously attempted. Several
underlying principles of systemic delivery and distant
target cell transduction have already been validated for
oncolytic virotherapy, where antigen-specific (for hom-
ing) T cells delivered oncolytic measles virus particles
to control metastatic growth [28, 29]. Combining these
principles with LV hitchhiking, i.e., cellular vector
capture by carrier cells, ex vivo protection from elimin-
ation by the host innate immune surveillance, chemo-
taxis to the BM microenvironment, and in situ delivery
to BM stem cells may confer functional correction in
FA [30]. We systematically simulated the critical
aspects of in situ gene delivery, including secondary
transduction and clearance of carrier cells. Consider-
able evidence supports the involvement of CXCR4-
SDF-1α as the critical axis for homing to the bone
marrow compartment [31–33]. In proof of principle
studies, we used low-dose radiation to elicit SDF-1α-
induced homing of carrier HSPCs to the bone marrow
to mediate in situ delivery of the therapeutic LV-GFP-
FANCC vector to endogenous Fancc–/– HSPCs. Our
model relies on congenic HSPCs as carriers for vector
delivery to recipient HSPCs. For clinical translation,
non-radiation based strategies, including inducible sui-
cide genes (HSVtk, iCaspase-9), would be preferable to
effectively eliminate the carrier cell population in vivo
[34]. Finally, the in vivo selection of a small number of
transduced cells is a critical component of our ap-
proach. Clonal expansion of spontaneously corrected
HSPCs under naturally occurring positive selection
suggests that a minimal number of corrected cells can
lead to clinical reversal of cytopenias in FA patients
[19–21]. Hence, we propose that a small population of
functionally corrected FA HSPCs via 2° TD can restore
hematopoiesis in the FA patients using optimal in vivo
selection methods [35]. In aggregate, the described
approach of in situ cellular delivery and phenotypic
correction of HSPCs may be suitable to incorporate
while designing gene therapy protocols for FA.
Additional file
Additional file 1: Materials and methods. (DOCX 16 kb)
Abbreviations
BM: Bone marrow; FA: Fanconi anemia; GFP: Green fluorescent protein;
HSC: Hematopoietic stem cell; HSPC: Hematopoietic stem and progenitor cell;
LV: Lentiviral vector; MMC: Mitomycin-C; SDF-1α: Stromal-derived factor-1α;
TD: Transduction
Funding
These studies were funded in part by grants from the “Friends of Doernbecher”
(PK) and R01HL90765 (PK).
Availability of data and materials
Materials and methods are available online (Additional file 1).
Authors’ contributions
SCV, NAG, and PK conceived and designed the experiments. PK and SCV
analyzed the data and wrote the manuscript. SCV and NAG conducted
in vitro and in vivo experiments. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Pediatrics, Oregon Health & Science University, Portland, OR
97239, USA. 2Papé Family Pediatric Research Institute, Oregon Health &
Science University, L321, Portland, OR 97239, USA. 3Present address:
Molecular, Cellular, Developmental Biology and Genetics, University of
Minnesota, Minneapolis, MN 55455, USA.
Received: 6 August 2016 Revised: 14 October 2016
Accepted: 26 October 2016
References
1. Duxin JP, Walter JC. What is the DNA repair defect underlying Fanconi
anemia? Curr Opin Cell Biol. 2015;37:49–60.
2. Bluteau D, Masliah-Planchon J, Clairmont C, Rousseau A, Ceccaldi R, Dubois
d’Enghien C, et al. Biallelic inactivation of REV7 is associated with Fanconi
anemia. J Clin Invest. 2016;126:3580–4.
3. Sumpter Jr R, Sirasanagandla S, Fernandez AF, Wei Y, Dong X, Franco L,
et al. Fanconi anemia proteins function in mitophagy and immunity. Cell.
2016;165:867–81.
4. Kaschutnig P, Bogeska R, Walter D, Lier A, Huntscha S, Milsom MD. The
Fanconi anemia pathway is required for efficient repair of stress-induced
DNA damage in haematopoietic stem cells. Cell Cycle. 2015;14:2734–42.
5. Vincent CL, Primack WA, Hipps J, Kasow KA. Sequential renal and bone
marrow transplants in a child with Fanconi anemia. Pediatr Transplant.
2016;20:146–50.
6. Li H, Xu Q. A successful second stem cell transplantation in Fanconi
anemia: a case report. Transplant Proc. 2015;47:2298–300.
7. Molina-Estevez FJ, Nowrouzi A, Lozano ML, Galy A, Charrier S, von Kalle C,
et al. Lentiviral-mediated gene therapy in Fanconi anemia-A mice reveals
long-term engraftment and continuous turnover of corrected HSCs. Curr
Gene Ther. 2015;15:550–62.
8. Walsh CE, Grompe M, Vanin E, Buchwald M, Young NS, Nienhuis AW, et al.
A functionally active retrovirus vector for gene therapy in Fanconi anemia
group C. Blood. 1994;84:453–9.
9. Cavazzana M. Hematopoietic stem cell gene therapy: progress on the
clinical front. Hum Gene Ther. 2014;25:165–70.
10. Kelly PF, Radtke S, von Kalle C, Balcik B, Bohn K, Mueller R, et al. Stem cell
collection and gene transfer in Fanconi anemia. Mol Ther. 2007;15:211–9.
11. Cohen-Haguenauer O, Peault B, Bauche C, Daniel MT, Casal I, Levy V, et al.
In vivo repopulation ability of genetically corrected bone marrow cells
from Fanconi anemia patients. Proc Natl Acad Sci U S A. 2006;103:2340–5.
12. Jacome A, Navarro S, Casado JA, Rio P, Madero L, Estella J, et al. A simplified
approach to improve the efficiency and safety of ex vivo hematopoietic
gene therapy in Fanconi anemia patients. Hum Gene Ther. 2006;17:245–50.
Chakkaramakkil Verghese et al. Stem Cell Research & Therapy  (2016) 7:170 Page 6 of 7
13. Habi O, Girard J, Bourdages V, Delisle MC, Carreau M. Correction of Fanconi
anemia group C hematopoietic stem cells following intrafemoral gene
transfer. Anemia. 2010;2010:13. doi:10.1155/2010/947816.
14. Wang X, Shin SC, Chiang AF, Khan I, Pan D, Rawlings DJ, et al. Intraosseous
delivery of lentiviral vectors targeting factor VIII expression in platelets
corrects murine hemophilia A. Mol Ther. 2015;23:617–26.
15. Pais-Correia AM, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A,
et al. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell
transmission at virological synapses. Nat Med. 2010;16:83–9.
16. Cavrois M, Neidleman J, Kreisberg JF, Greene WC. In vitro derived dendritic
cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions.
PLoS Pathog. 2007;3:e4.
17. Balzarini J, Van Damme L. Intravaginal and intrarectal microbicides to
prevent HIV infection. CMAJ. 2005;172:461–4.
18. Skinner AM, Chakkaramakkil Verghese S, Kurre P. Cell-cell transmission of
VSV-G pseudotyped lentivector particles. PLoS One. 2013;8:e74925.
19. O’Neill LS, Skinner AM, Woodward JA, Kurre P. Entry kinetics and cell-cell
transmission of surface-bound retroviral vector particles. J Gene Med. 2010;
12:463–76.
20. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-
fluorescent Cre reporter mouse. Genesis. 2007;45:593–605.
21. Yabe M, Shimizu T, Morimoto T, Koike T, Takakura H, Tsukamoto H, et al.
Matched sibling donor stem cell transplantation for Fanconi anemia
patients with T-cell somatic mosaicism. Pediatr Transplant. 2012;16:340–5.
22. Gregory Jr JJ, Wagner JE, Verlander PC, Levran O, Batish SD, Eide CR, et al.
Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in
lymphohematopoietic stem cells. Proc Natl Acad Sci U S A. 2001;98:2532–7.
23. Zhang H, Kozono DE, O’Connor KW, Vidal-Cardenas S, Rousseau A, Hamilton
A, et al. TGF-beta inhibition rescues hematopoietic stem cell defects and
bone marrow failure in Fanconi anemia. Cell Stem Cell. 2016;18:668–81.
24. Bosch PC, Bogliolo M, Surralles J. Activation of the Fanconi anemia/BRCA
pathway at low doses of ionization radiation. Mutat Res Genet Toxicol
Environ Mutagen. 2015;793:9–13.
25. Muller LU, Milsom MD, Harris CE, Vyas R, Brumme KM, Parmar K, et al.
Overcoming reprogramming resistance of Fanconi anemia cells. Blood.
2012;119:5449–57.
26. Muller LU, Williams DA. Finding the needle in the hay stack: hematopoietic
stem cells in Fanconi anemia. Mutat Res. 2009;668:141–9.
27. Brown BD, Sitia G, Annoni A, Hauben E, Sergi LS, Zingale A, et al. In vivo
administration of lentiviral vectors triggers a type I interferon response that
restricts hepatocyte gene transfer and promotes vector clearance. Blood.
2007;109:2797–805.
28. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L, et al. Tumor-
targeted, systemic delivery of therapeutic viral vectors using hitchhiking on
antigen-specific T cells. Nat Med. 2005;11:1073–81.
29. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ,
et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic
measles viruses in cancer virotherapy. Mol Ther. 2007;15:114–22.
30. Kim J, Hall RR, Lesniak MS, Ahmed AU. Stem cell-based cell carrier for
targeted oncolytic virotherapy: translational opportunity and open
questions. Viruses. 2015;7:6200–17.
31. Vagima Y, Lapid K, Kollet O, Goichberg P, Alon R, Lapidot T. Pathways
implicated in stem cell migration: the SDF-1/CXCR4 axis. Methods Mol
Biol. 2011;750:277–89.
32. Cencioni C, Capogrossi MC, Napolitano M. The SDF-1/CXCR4 axis in stem
cell preconditioning. Cardiovasc Res. 2012;94:400–7.
33. Sahin AO, Buitenhuis M. Molecular mechanisms underlying adhesion and
migration of hematopoietic stem cells. Cell Adh Migr. 2012;6:39–48.
34. Zhan H, Gilmour K, Chan L, Farzaneh F, McNicol AM, Xu JH, et al.
Production and first-in-man use of T cells engineered to express a
HSVTK-CD34 sort-suicide gene. PLoS One. 2013;8:e77106.
35. Noll M, Bateman RL, D’Andrea AD, Grompe M. Preclinical protocol for
in vivo selection of hematopoietic stem cells corrected by gene therapy
in Fanconi anemia group C. Mol Ther. 2001;3:14–23.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chakkaramakkil Verghese et al. Stem Cell Research & Therapy  (2016) 7:170 Page 7 of 7
